Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units

An innovative simple, rapid and sensitive spectrophotometric method was developed for the simultaneous analysis of sofosbuvir (SOF) and ledipasvir (LED) in their combined dosage forms. Sofosbuvir with ledipasvir (SOF/LED) as a combined dosage form was tried at the pandemic COVID 19 crisis. This technique has the advantages of both zero order and first order spectrophotometry. The zero and first derivative amplitudes were measured at 274.2 nm for SOF (zero crossing point of LED in first derivative spectrum) and 314 nm for LED (zero crossing point of SOF in first derivative spectrum) over the concentration range of 2.0-50.0 mu g mL(-1) with coefficients of determination (R-2) > 0.9999 for both drugs and mean percentage recoveries of 100.25 +/- 1.61 and 99.85 +/- 0.99 for SOF and LED; respectively.This original method was validated according to ICH requirements and statistically compared to published comparison methods. This method was applied to estimate the average content and the uniformity of dosage units of SOF/LED combined dosage form according to British Pharmacopeia requirements.(c) 2021 Elsevier B.V. All rights reserved.

Automated summary

A novel spectrophotometric method was developed for simultaneous analysis of sofosbuvir and ledipasvir in their combined dosage forms. This method offers the advantages of simplicity, rapidity, and sensitivity, making it suitable for use in the COVID-19 crisis.